.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Johnson and Johnson
Queensland Health
Teva
McKinsey
US Army
Dow
Chubb
Moodys
Farmers Insurance

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,344,783

« Back to Dashboard

Details for Patent: 5,344,783

Title: Platelet aggregation inhibitors
Abstract:An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of the PAI in a wide range of snake venom samples were accomplished. The purified PAI from several of these active snake venoms is described. In addition, PAIs lacking the Arg-Gly-Asp adhesion sequence but containing Lys-Gly-Asp are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.
Inventor(s): Scarborough; Robert M. (Hayward, CA), Charo; Israel F. (Lafayette, CA)
Assignee: COR Therapeutics, Inc. (South San Francisco, CA)
Filing Date:Jul 12, 1993
Application Number:08/091,392
Claims:1. A method for selecting a compound that selectively inhibits platelet aggregation over other cellular activities mediated by integrins, which method comprises:

(a) contacting a sample of said compound with purified GP IIb-IIIa receptor coated onto a solid support in the presence of a solution of labeled fibrinogen or von Willebrand Factor under conditions wherein fibrinogen or von Willebrand factor binds to said GP IIb-IIIa;

(b) measuring the binding of fibrinogen or von Willebrand factor to GP IIb-IIIa in comparison to the binding of fibrinogen or von Willebrand factor to GP IIb-IIIa in a control which does not contain said compound by measuring the amount of bound labeled fibrinogen;

(c) determining the inhibition in (b);

(d) contacting a sample of said compound with purified vitronectin receptor coated onto a solid support in the presence of a solution of labeled vitronectin under conditions wherein vitronectin binds to said vitronectin receptor;

(e) measuring the binding of vitronectin to vitronectin receptor in comparison to the binding of vitronectin to vitronectin receptor in a control which does not contain said compound by measuring the amount of bound labeled vitronectin;

(f) determining the inhibition in (e); and

(g) selecting a sample in which the relative inhibition determined in (c) is at east twice that determined in (f).

2. A method for selecting a compound that selectively inhibits platelet aggregation over other cellular activities mediated by integrins, which method comprises:

(a) contacting a sample of said compound with purified GP IIb-IIIa receptor coated onto a solid support in the presence of a solution of labeled fibrinogen or von Willebrand Factor under conditions wherein fibrinogen or von Willebrand factor binds to said GP IIb-IIIa;

(b) measuring the binding of fibrinogen or von Willebrand factor to GP IIb-IIIa in comparison to the binding of fibrinogen or von Willebrand factor to GP IIb-IIIa in a control which does not contain said compound by measuring the amount of bound labeled fibrinogen;

(c) determining the inhibition in (b);

(d) contacting a sample of said compound with purified fibronectin receptor coated onto a solid support in the presence of a solution of labeled fibronectin under conditions wherein fibronectin binds to said fibronectin receptor;

(e) measuring the binding of fibronectin to fibronectin receptor in comparison to the binding of fibronectin to fibronectin receptor in a control which does not contain said compound by measuring the amount of bound labeled fibronectin;

(f) determining the inhibition in (e); and

(g) selecting a sample in which the relative inhibition determined in (c) is at least twice that determined in (f).

3. The method of claim 1, comprising the further steps of:

(h) contacting a sample selected in (g) with purified fibronectin receptor coated onto a solid support in the presence of a solution of labeled fibronectin under conditions wherein fibronectin binds to said fibronectin receptor;

(i) measuring the binding of fibronectin to fibronectin receptor in comparison to the binding of fibronectin to fibronectin receptor in a control which does not contain said compound by measuring the amount of bound labeled fibronectin;

(j) determining the inhibition in (i); and

(k) selecting a sample in which the relative inhibition determined in (c) is at least twice that determined in (j).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
US Department of Justice
Mallinckrodt
Teva
Queensland Health
Argus Health
Express Scripts
Boehringer Ingelheim
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot